Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
Status: | Active, not recruiting |
---|---|
Conditions: | Other Indications, Cardiology, Gastrointestinal |
Therapuetic Areas: | Cardiology / Vascular Diseases, Gastroenterology, Other |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | May 2014 |
End Date: | June 2016 |
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
The primary objective is to evaluate the clinical benefit of CureXcell® as adjunct to
Standard of Care in the treatment of Chronic Venous Leg Ulcers. CureXcell® is a cell based
therapy, containing activated homologous white blood cells prepared from donated healthy
whole blood. A total of 252 patients will be randomized to receive either CureXcell® or
Placebo.
Standard of Care in the treatment of Chronic Venous Leg Ulcers. CureXcell® is a cell based
therapy, containing activated homologous white blood cells prepared from donated healthy
whole blood. A total of 252 patients will be randomized to receive either CureXcell® or
Placebo.
Inclusion Criteria:
- Ankle Brachial Pressure Index (ABI) ≥ 0.80
- Venous insufficiency confirmed by duplex Doppler ultrasound
- Presence of a venous leg ulcer, unresponsive to Standard of Care treatment for at
least 4 weeks and between ≥ 1 cm2 and ≤ 17.1 cm2 at screening; and between ≥ 1 cm2
and ≤ 12cm2 at the Baseline Visit
Exclusion Criteria:
- Target Ulcer has decreased >30% in size from Screening to Baseline
- Documented history of osteomyelitis at the Target Ulcer location within 6 months
preceding the Baseline Visit.
- Patients who are unable to tolerate multi-layer compression therapy.
- Ulcer, which in the opinion of the Investigator is suspicious for cancer.
- Any malignancy within the past 5 years, excluding successfully treated basal cell
carcinoma or squamous cell carcinoma without evidence of metastases.
- History of radiation at the Target Ulcer site in previous 12 months prior to Baseline
Visit.
- Patients with clinically significant claudication
- Current sepsis
- Patients with known history of significantly compromised immunity for any reason
including radiation therapy, chemotherapy or HIV
We found this trial at
29
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials